Skip to main content
Erschienen in: Journal of Clinical Immunology 1/2014

01.07.2014

Natural Autoantibodies to Fcγ Receptors in Intravenous Immunoglobulins

verfasst von: Hicham Bouhlal, Denis Martinvalet, Jean-Luc Teillaud, Catherine Fridman, Michel D. Kazatchkine, Jagadeesh Bayry, Sébastien Lacroix-Desmazes, Srini V. Kaveri

Erschienen in: Journal of Clinical Immunology | Sonderheft 1/2014

Einloggen, um Zugang zu erhalten

Abstract

A considerable progress has been achieved in the comprehension of the cellular and molecular mechanisms that account for the therapeutic benefit of intravenous immunoglobulin (IVIg) in several autoimmune and inflammatory conditions. However, the precise mechanisms responsible for such a wide range of biological activities have not been proven unambiguously. A wide range of specificities have been identified within IVIg including idiotypes of immunoglobulins, T cell receptor, HLA molecules, several cell surface molecules of immunological importance such as CD4, CD5, Fas, BAFF, cytokines and cytokine receptors, chemokine receptors, CD40 among others. Here we identify and characterize the natural autoantibodies of IgG isotype directed against the human Fc receptors. We show that the F(ab′)2 of IVIg recognize the FcγRIII (CD16) and FcγRII (CD32). Interestingly, the immunopurified anti-FcγIII and anti-FcγII antibodies isolated from IVIg bind soluble and membrane-bound FcR and inhibit rosette formation. Altogether, these results along with previous reports provide pointers on the existence of functionally relevant natural autoantibodies towards a wide range of self-motifs that may participate in regulation of the immune response. Their presence in the therapeutic immunoglobulin preparations may explain at least in part, the beneficial effect of IVIg in autoimmune diseases.
Literatur
1.
Zurück zum Zitat Coutinho A, Kazatchkine MD, Avrameas S. Natural autoantibodies. Curr Opin Immunol. 1995;7:812–8.PubMedCrossRef Coutinho A, Kazatchkine MD, Avrameas S. Natural autoantibodies. Curr Opin Immunol. 1995;7:812–8.PubMedCrossRef
2.
Zurück zum Zitat Durandy A, Kaveri SV, Kuijpers TW, Basta M, Miescher S, Ravetch JV, et al. Intravenous immunoglobulins: understanding properties and mechanisms. Clin Exp Immunol. 2009;158:2–13.PubMedCentralPubMedCrossRef Durandy A, Kaveri SV, Kuijpers TW, Basta M, Miescher S, Ravetch JV, et al. Intravenous immunoglobulins: understanding properties and mechanisms. Clin Exp Immunol. 2009;158:2–13.PubMedCentralPubMedCrossRef
3.
Zurück zum Zitat Madi A, Bransburg-Zabary S, Kenett DY, Ben-Jacob E, Cohan IR. The natural autoantibody repertoire in newborns and adults. Adv Exp Med Biol. 2012;750:198–212.PubMedCrossRef Madi A, Bransburg-Zabary S, Kenett DY, Ben-Jacob E, Cohan IR. The natural autoantibody repertoire in newborns and adults. Adv Exp Med Biol. 2012;750:198–212.PubMedCrossRef
4.
Zurück zum Zitat Avrameas S, Selmi C. Natural autoantibodies in the physiology and pathophysiology of the immune system. J Autoimmun. 2013;41:46–9.PubMedCrossRef Avrameas S, Selmi C. Natural autoantibodies in the physiology and pathophysiology of the immune system. J Autoimmun. 2013;41:46–9.PubMedCrossRef
6.
Zurück zum Zitat Nimmerjahn F, Ravetch JV. FcγRs in health and disease. Curr Top Microbiol Immunol. 2011;350:105–25.PubMed Nimmerjahn F, Ravetch JV. FcγRs in health and disease. Curr Top Microbiol Immunol. 2011;350:105–25.PubMed
8.
Zurück zum Zitat Nimmerjahn F, Ravetch JV. Fcγ receptors as regulators of immune responses. Nat Rev Immunol. 2008;8:34–47.PubMedCrossRef Nimmerjahn F, Ravetch JV. Fcγ receptors as regulators of immune responses. Nat Rev Immunol. 2008;8:34–47.PubMedCrossRef
9.
Zurück zum Zitat Loone RJ, Huggins J. Use of intravenous immunoglobulin G (IVIG). Best Pract Res Clin Haematol. 2006;19:3–25.CrossRef Loone RJ, Huggins J. Use of intravenous immunoglobulin G (IVIG). Best Pract Res Clin Haematol. 2006;19:3–25.CrossRef
10.
Zurück zum Zitat Vani J, Elluru S, Negi VS, Lacroix-Desmazes S, Kazatchkine MD, Bayry J, et al. Role of natural antibodies in immune homeostasis: IVIg perspective. Autoimmun Rev. 2008;7:440–4.PubMedCrossRef Vani J, Elluru S, Negi VS, Lacroix-Desmazes S, Kazatchkine MD, Bayry J, et al. Role of natural antibodies in immune homeostasis: IVIg perspective. Autoimmun Rev. 2008;7:440–4.PubMedCrossRef
11.
Zurück zum Zitat Bonagura VR. Using intravenous immunoglobulin (IVIG) to treat patients with primary immune deficiency disease. J Clin Immunol. 2013;33:S90–4.PubMedCrossRef Bonagura VR. Using intravenous immunoglobulin (IVIG) to treat patients with primary immune deficiency disease. J Clin Immunol. 2013;33:S90–4.PubMedCrossRef
12.
Zurück zum Zitat Damianovich M, Blank M, Raiter A, Hardy B, Shoenfeld Y. Anti-vascular endothelial growth factor (VEGF) specific activity of intravenous immunoglobulin (IVIg). Int Immunol. 2009;21:1057–63.PubMedCrossRef Damianovich M, Blank M, Raiter A, Hardy B, Shoenfeld Y. Anti-vascular endothelial growth factor (VEGF) specific activity of intravenous immunoglobulin (IVIg). Int Immunol. 2009;21:1057–63.PubMedCrossRef
13.
Zurück zum Zitat Dunn-Siegrist I, Leger O, Daubeuf B, Poitevin Y, Dépis F, Herren S, et al. Pivotal involvement of Fcγ receptor IIA in the neutralization of lipopolysaccharide signaling via a potent novel anti-TLR4 monoclonal antibody 15C1. J Biol Chem. 2007;282:34817–27.PubMedCrossRef Dunn-Siegrist I, Leger O, Daubeuf B, Poitevin Y, Dépis F, Herren S, et al. Pivotal involvement of Fcγ receptor IIA in the neutralization of lipopolysaccharide signaling via a potent novel anti-TLR4 monoclonal antibody 15C1. J Biol Chem. 2007;282:34817–27.PubMedCrossRef
14.
Zurück zum Zitat Astier A, de la Salle H, de la Salle C, Bieber T, Esposito-Farese ME, Freund M, et al. Human epidermal Langerhans cells secrete a soluble receptor for IgG (Fc gamma RII/CD32) that inhibits the binding of immune complexes to Fc gamma R+ cells. J Immunol. 1994;152:201–12.PubMed Astier A, de la Salle H, de la Salle C, Bieber T, Esposito-Farese ME, Freund M, et al. Human epidermal Langerhans cells secrete a soluble receptor for IgG (Fc gamma RII/CD32) that inhibits the binding of immune complexes to Fc gamma R+ cells. J Immunol. 1994;152:201–12.PubMed
15.
Zurück zum Zitat D’Arrigo C, Candal-Couto JJ, Greer M, Veale DJ, Woof JM. Human neutrophil Fc receptor-mediated adhesion under flow: a hollow fibre model of intravascular arrest. Clin Exp Immunol. 1995;100:173–9.PubMedCentralPubMedCrossRef D’Arrigo C, Candal-Couto JJ, Greer M, Veale DJ, Woof JM. Human neutrophil Fc receptor-mediated adhesion under flow: a hollow fibre model of intravascular arrest. Clin Exp Immunol. 1995;100:173–9.PubMedCentralPubMedCrossRef
16.
Zurück zum Zitat Vivier E, da Silva AJ, Ackerly M, Levine H, Rudd CE, Anderson P. Association of a 70-kDa tyrosine phosphoprotein with the CD16: zeta: gamma complex expressed in human natural killer cells. Eur J Immunol. 1993;23:1872–6.PubMedCrossRef Vivier E, da Silva AJ, Ackerly M, Levine H, Rudd CE, Anderson P. Association of a 70-kDa tyrosine phosphoprotein with the CD16: zeta: gamma complex expressed in human natural killer cells. Eur J Immunol. 1993;23:1872–6.PubMedCrossRef
17.
Zurück zum Zitat Koenderman L, Hermans SW, Capel PJ, van de Winkel JG. Granulocyte-macrophage colony-stimulating factor induces sequential activation and deactivation of binding via a low-affinity IgG Fc receptor, hFc gamma RII, on human eosinophils. Blood. 1993;81:2413–9.PubMed Koenderman L, Hermans SW, Capel PJ, van de Winkel JG. Granulocyte-macrophage colony-stimulating factor induces sequential activation and deactivation of binding via a low-affinity IgG Fc receptor, hFc gamma RII, on human eosinophils. Blood. 1993;81:2413–9.PubMed
18.
Zurück zum Zitat Bayry J, Negi VS, Kaveri SV. Intravenous immunoglobulin therapy in rheumatic diseases. Nat Rev Rheumatol. 2011;7:349–59.PubMedCrossRef Bayry J, Negi VS, Kaveri SV. Intravenous immunoglobulin therapy in rheumatic diseases. Nat Rev Rheumatol. 2011;7:349–59.PubMedCrossRef
19.
Zurück zum Zitat Wong A, Kenny TP, Ermel R, Robbins DL. IgG3 reactive rheumatoid factor in rheumatoid arthritis: etiologic and pathogenic considerations. Autoimmunity. 1994;19:199–210.PubMedCrossRef Wong A, Kenny TP, Ermel R, Robbins DL. IgG3 reactive rheumatoid factor in rheumatoid arthritis: etiologic and pathogenic considerations. Autoimmunity. 1994;19:199–210.PubMedCrossRef
20.
Zurück zum Zitat Boros P, Chen JM, Bona C, Unkeless JC. Autoimmune mice make anti-Fc gamma receptor antibodies. J Exp Med. 1990;171:1581–95.PubMedCrossRef Boros P, Chen JM, Bona C, Unkeless JC. Autoimmune mice make anti-Fc gamma receptor antibodies. J Exp Med. 1990;171:1581–95.PubMedCrossRef
21.
Zurück zum Zitat Boros P, Odin JA, Chen J, Unkeless JC. Specificity and class distribution of Fc gamma R-specific autoantibodies in patients with autoimmune disease. J Immunol. 1994;152:302–6.PubMed Boros P, Odin JA, Chen J, Unkeless JC. Specificity and class distribution of Fc gamma R-specific autoantibodies in patients with autoimmune disease. J Immunol. 1994;152:302–6.PubMed
22.
Zurück zum Zitat Sajedi V, Movahedi M, Aghamohammadi A, Gharagozlou M, Shafiei A, Soheili H, et al. Comparison between sensitivity of autologous skin serum test and autologous plasma skin test in patients with Chronic Idiopathic Urticaria for detection of antibody against IgE or IgE receptor (FcεRIα). Iran J Allergy Asthma Immunol. 2011;10:111–7.PubMed Sajedi V, Movahedi M, Aghamohammadi A, Gharagozlou M, Shafiei A, Soheili H, et al. Comparison between sensitivity of autologous skin serum test and autologous plasma skin test in patients with Chronic Idiopathic Urticaria for detection of antibody against IgE or IgE receptor (FcεRIα). Iran J Allergy Asthma Immunol. 2011;10:111–7.PubMed
23.
Zurück zum Zitat Mannoor K, Xu Y, Chen C. Natural autoantibodies and associated B cells in immunity and autoimmunity. Autoimmunity. 2013;46:138–47.PubMedCrossRef Mannoor K, Xu Y, Chen C. Natural autoantibodies and associated B cells in immunity and autoimmunity. Autoimmunity. 2013;46:138–47.PubMedCrossRef
24.
Zurück zum Zitat Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science. 2001;291:484–6.PubMedCrossRef Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science. 2001;291:484–6.PubMedCrossRef
25.
Zurück zum Zitat Bierlinga P. Intravenous immunoglobulin for autoimmune thrombocytopenic purpura. Hum Immunol. 2005;4:387–94.CrossRef Bierlinga P. Intravenous immunoglobulin for autoimmune thrombocytopenic purpura. Hum Immunol. 2005;4:387–94.CrossRef
26.
Zurück zum Zitat Rouard H, Tamasdan S, Moncuit J, Moutel S, Michon J, Fridman WH, et al. Fc receptors as targets for immunotherapy. Int Rev Immunol. 1997;16:147–85.PubMedCrossRef Rouard H, Tamasdan S, Moncuit J, Moutel S, Michon J, Fridman WH, et al. Fc receptors as targets for immunotherapy. Int Rev Immunol. 1997;16:147–85.PubMedCrossRef
27.
Zurück zum Zitat Sautès C, Galinha A, Bouchard C, Mazières N, Spagnoli R, Fridman WH. Recombinant soluble Fc gamma receptors: production, purification and biological activities. J Chromatogr B Biomed Appl. 1994;662:197–207.PubMedCrossRef Sautès C, Galinha A, Bouchard C, Mazières N, Spagnoli R, Fridman WH. Recombinant soluble Fc gamma receptors: production, purification and biological activities. J Chromatogr B Biomed Appl. 1994;662:197–207.PubMedCrossRef
28.
Zurück zum Zitat Teillaud JL, Bouchard C, Astier A, Teillaud C, Tartour E, Michon J, et al. Natural and recombinant soluble low-affinity Fc gamma R: detection, purification, and functional activities. Immunomethods. 1994;4:48–64.PubMedCrossRef Teillaud JL, Bouchard C, Astier A, Teillaud C, Tartour E, Michon J, et al. Natural and recombinant soluble low-affinity Fc gamma R: detection, purification, and functional activities. Immunomethods. 1994;4:48–64.PubMedCrossRef
29.
Zurück zum Zitat Galon J, Gauchat JF, Mazières N, Spagnoli R, Storkus W, Lötze M, et al. Soluble Fcgamma receptor type III (FcgammaRIII, CD16) triggers cell activation through interaction with complement receptors. J Immunol. 1996;157:1184–92.PubMed Galon J, Gauchat JF, Mazières N, Spagnoli R, Storkus W, Lötze M, et al. Soluble Fcgamma receptor type III (FcgammaRIII, CD16) triggers cell activation through interaction with complement receptors. J Immunol. 1996;157:1184–92.PubMed
30.
Zurück zum Zitat de la Salle H, Galon J, Bausinger H, Spehner D, Bohbot A, Cohen J, et al. Soluble CD16/Fc gamma RIII induces maturation of dendritic cells and production of several cytokines including IL-12. Adv Exp Med Biol. 1997;417:345–52.PubMedCrossRef de la Salle H, Galon J, Bausinger H, Spehner D, Bohbot A, Cohen J, et al. Soluble CD16/Fc gamma RIII induces maturation of dendritic cells and production of several cytokines including IL-12. Adv Exp Med Biol. 1997;417:345–52.PubMedCrossRef
Metadaten
Titel
Natural Autoantibodies to Fcγ Receptors in Intravenous Immunoglobulins
verfasst von
Hicham Bouhlal
Denis Martinvalet
Jean-Luc Teillaud
Catherine Fridman
Michel D. Kazatchkine
Jagadeesh Bayry
Sébastien Lacroix-Desmazes
Srini V. Kaveri
Publikationsdatum
01.07.2014
Verlag
Springer US
Erschienen in
Journal of Clinical Immunology / Ausgabe Sonderheft 1/2014
Print ISSN: 0271-9142
Elektronische ISSN: 1573-2592
DOI
https://doi.org/10.1007/s10875-014-0019-2

Weitere Artikel der Sonderheft 1/2014

Journal of Clinical Immunology 1/2014 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.